Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients.

ABSTRACT: Hyaluronan (HA) is associated with innate immune response activation and may be a marker of allograft dysfunction in lung transplant recipients. This was a prospective, single center study comparing levels of bronchioalveolar lavage (BAL) and serum HA and the HA immobilizer LYVE-1 in lung transplant recipients with and without acute cellular rejection (ACR). Chronic lung allograft dysfunction (CLAD)-free survival was also evaluated based on HA and LYVE-1 levels. 78 recipients were enrolled with a total of 115 diagnostic biopsies and 1.5 years of median follow-up. Serum HA was correlated with BAL HA (r?=?0.25, p?=?0.01) and with serum LYVE-1 (r?=?0.32, p?=?0.002). There was significant variation in HA and LYVE-1 over time, regardless of ACR status. Levels of serum HA (median 74.7 vs 82.7, p?=?0.69), BAL HA (median 149.4 vs 134.5, p?=?0.39), and LYVE-1 (mean 190.2 vs 183.8, p?=?0.72) were not associated with ACR. CLAD-free survival was not different in recipients with any episode of elevated serum HA (HR?=?1.5, 95% CI?=?0.3-7.7, p?=?0.61) or BAL HA (HR?=?0.94, 95% CI?=?0.2-3.6, p?=?0.93). These results did not differ when stratified by bilateral transplant status. In this small cohort, serum HA, BAL HA, and LYVE-1 levels are not associated with ACR or CLAD-free survival in lung transplant recipients.

SUBMITTER: Courtwright AM 

PROVIDER: S-EPMC6588572 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature